Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
Principal Investigator: Dr. Sreenivasa Chandana
For more information on this trial, read its profile on clinicaltrials.gov here.